Oxford BioDynamics PLC Collaboration into identifying diagnosis of Autism
12 November 2018 - 6:00PM
RNS Non-Regulatory
TIDMOBD
Oxford BioDynamics PLC
12 November 2018
12 November 2018
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics enters into collaboration to identify
EpiSwitch(TM) biomarkers for the diagnosis of Autism Spectrum
Disorder (ASD)
-- Diagnosis of ASD is challenging, indicating the need for accurate diagnostic biomarkers.
-- Agreement signed with Casa Sollievo della Sofferenza, a
recognised research and biomedical institution of national
importance in Italy.
Oxford BioDynamics Plc announces that it has signed a
collaboration agreement with Casa Sollievo della Sofferenza, a
recognised research and biomedical institution of national
importance in Italy, to identify EpiSwitch(TM) biomarkers for the
blood-based diagnosis of Autism Spectrum Disorder (ASD).
The agreement between OBD and Casa Sollievo della Sofferenza
aims to develop a diagnostic biomarker assay for ASD, using the
EpiSwitch(TM) technology platform. Casa Sollievo della Sofferenza
will supply blood samples from both autistic subjects and healthy
controls. These will then be screened at high resolution for
epigenetic changes, in the form of chromosome conformational
signatures, by OBD using the EpiSwitch(TM) high throughput
technology platform. In addition to identifying a potential
diagnostic biomarker assay, OBD hopes to expand the epigenetic
knowledge base for ASD, facilitating future research and
pharmaceutical development into this spectrum of disorders.
ASD, which is thought to be caused by a complex interaction of
genetic, epigenetic and environmental factors, represents a group
of neurodevelopmental disorders, characterised by problems with
social interaction and communication. It is estimated that
approximately 1 in every 100 people in the UK has ASD. There is no
cure for ASD, however speech and language therapy, occupational
therapy and educational support provide great benefits for these
patients. Earlier diagnosis would allow more timely intervention,
improving the results of treatment and enhancing clinical
outcomes.
Currently, diagnosis for ASD remains challenging due to broad
ranging symptoms and differential progression and manifestation of
the disorder. As the EpiSwitch(TM) platform monitors the
environmental impact on the genome, it is well placed to identify
biomarkers for diagnosing ASD through minimally invasive blood
sampling.
Alexandre Akoulitchev, Chief Scientific Officer of Oxford
BioDynamics, said:
"We are looking forward to joining forces with the Casa Sollievo
della Sofferenza team, to develop reliable non-invasive biomarkers
for ASD. We are highly appreciative of the great expertise and ASD
insights from our Italian colleagues. We strongly believe our work
will help to improve the understanding of epigenetic controls and
mechanisms behind this disorder. This agreement further
demonstrates rising interest in our proprietary technology,
EpiSwitch(TM), which offers results of unique value and clinical
utility in biomarker discovery and disease understanding for a
broad spectrum of complex indications, from immune-oncology and
autoimmune conditions, to neurodegeneration, psychiatric and
neurodevelopmental conditions."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGGQAGUPRGQB
(END) Dow Jones Newswires
November 12, 2018 02:00 ET (07:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024